First Oral Cellular Factor Drug For Tumor In Phase III Trials
This article was originally published in PharmAsia News
Executive Summary
Shanghai Institute of Biochemistry and Cell Biology under the Chinese Academy of Sciences, Zhejiang University, Zhejiang Sci-Tech University and the Key Laboratory of Bioreactor and Biopharmacy of Zhejiang province recently announced they have successfully developed an orally administered granulocyte-macrophage colony-stimulating factor, which is currently in Phase III clinical trials. GM-CSF injection has been used clinically but it is inconvenient and patients suffer from side effects. The latest research, published by open-accessed online journal PloS One, shows that Chinese scientists have discovered a breakthrough method of oral absorption for the cellular factor drug, a world first in tumor bio-treatment. (Click here for more - Chinese Language)
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.